Caris Life Sciences to Present 32 Studies at ASCO 2026 Highlighting Advances in Precision Oncology
Caris Life Sciences, a leader in precision medicine, announced its participation in the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The company, along with its Precision Oncology Alliance and over 60 collaborating institutions, will present 32 studies. These studies cover a range of topics including breast, colorectal, lung, endometrial, and renal cell carcinoma, as well as pan-cancer analyses. The research focuses on multi-omic biomarker investigations and real-world data to enhance understanding of tumor biology and inform precision oncology approaches. Notable studies include those examining genetic ancestry's influence on melanoma and ESR1 amplification in breast cancer. The presentations aim to showcase the importance of comprehensive molecular profiling in advancing precision oncology. 
